QuellTX Logo

Quell Therapeutics named a “Fierce 15“ Company by FierceBiotech

London, 23 September 2019 – Quell Therapeutics, a biotechnology company focused on developing engineered T regulatory (Treg) cell therapies, announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.  

“We are thrilled to be named among the industry’s most exciting new biotech companies. At Quell we are taking a leadership position in the pioneering new field of Genetically Modified Regulatory T Cell therapies (modified Tregs), with the potential of modified Treg therapies to address conditions of immune dysfunction holding great promise for our patients,” said Iain McGill, Chief Executive Officer of Quell Therapeutics. “The talented and growing team at Quell is making rapid strides in developing our platform and building a pipeline of products to address a range of conditions including solid organ transplant rejection, autoimmune and inflammatory diseases. It is a tremendous honour that our approach and our team have been recognized with this Fierce 15 award.”

“This year has seen unrivalled scientific talent in the early-stage life sciences world, and it has been a pleasure to for us at FierceBiotech to speak to all 15 winners and hear their passion, progress and panache,” said Ben Adams, Senior Editor of FierceBiotech. “Each company brought something different, exciting and potentially life-changing for myriad patients around the world across a host of diseases and disorders, using cutting-edge science, top-notch teams and a drive to genuinely make the world a better place, despite the risks and challenges that, as ever in biotech, lay ahead.”

Further information:                                                                       

Julia Wilson

JW Communications

+44 (0) 7818 430877


Rebecca Willumson




About Quell Therapeutics

Quell Therapeutics is a privately held biotechnology company with a vision to become a leading engineered TRegs cell therapy company. The company is developing next generation engineered T-regulatory (TReg) cell therapies for a range of solid organ transplant and autoimmune conditions.

Quell Therapeutics was founded by Syncona in partnership with six leading experts in the TRegs field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and

Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader “Immune tolerance” in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School. 

About FierceBiotech:FierceBiotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com/signup


BioCentury – Quell: tweaking Tregs for persistence, potency and stability

 London-based Quell is among a new generation of companies springboarding off advances in CAR T cells and gene editing to develop more targeted Treg cell therapies with enhanced persistence, potency and stability.  To view the full article please click here...

Read More

Quell Therapeutics Expands Series A Financing to $84 Million

– Largest Series A in the Treg field – – Lead program is a first-in-class treatment targeting liver transplantation with engineered Treg cell therapy – – First program expected to enter the clinic in first half of 2022 – London,…...

Read More

Quell Therapeutics Enters a Collaborative Research Agreement with the University of Sheffield

Collaboration will accelerate Quell’s pipeline expansion into neuroinflammatory diseases London and Sheffield, UK – October 26, 2020 – Quell Therapeutics, a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced that the company has entered into a collaborative…...

Read More